ReviewInternational journal of molecular sciences2019
Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis through a Grade Analysis of Evidence.Orthopaedic surgery · 2021Pooled it
- Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials.BMC complementary medicine and therapies · 2021Pooled it
- Nutritional Support and Physical Modalities for People with Osteoporosis: Current Opinion.Nutrients · 2019Pooled it
- Pooled it
- Trial
- Site-Specific Associations Between CBCT-Derived Gray Value and Fractal Dimension and DEXA T-Scores in Postmenopausal Women: A Cross-Sectional Analytical Study.Clinical and experimental dental research · 2026Article
- Revolutionizing osteoporosis management: the emerging role of immunotherapeutic and next-generation therapies.Inflammopharmacology · 2025Review
- Combination of Pilose Antler Extract and Hydroxytyrosol Enhances Bone Mineral Density in Both Animals and Postmenopausal Women.Food science & nutrition · 2025Article
- Investigating the Role of Shikonin in Enhancing Osteogenesis and Angiogenesis for the Treatment of Osteoporosis.ACS omega · 2025Article
- Nrf2 Activation as a Therapeutic Target for Flavonoids in Aging-Related Osteoporosis.Nutrients · 2025Review
- Association of Osteoporosis with Tooth Loss and Dental Radiomorphometric Indices.Biomedicines · 2024Article
- Methyl-Beta-Cyclodextrin Restores Aberrant Bone Morphogenetic Protein 2-Signaling in Bone Marrow Stromal Cells Obtained from Aged C57BL/6 Mice.Journal of developmental biology · 2024Article
- Osteoporosis management-current and future perspectives - A systemic review.Journal of orthopaedics · 2024Review
- A mixture ofHeliyon · 2024Article
- Osteoporosis therapy using nanoparticles: a review.Annals of medicine and surgery (2012) · 2024Review
- A comprehensive review on 3D tissue models: Biofabrication technologies and preclinical applications.Biomaterials · 2024Review
- Insights into the Mechanism of Osteoporosis and the Available Treatment Options.Current pharmaceutical biotechnology · 2024Review
- Comparison of three different lactic acid bacteria-fermented proteins on RAW 264.7 osteoclast and MC3T3-E1 osteoblast differentiation.Scientific reports · 2023Article
- Quercetin suppresses ovariectomy-induced osteoporosis in rat mandibles by regulating autophagy and the NLRP3 pathway.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Drug Delivery and Therapy Strategies for Osteoporosis Intervention.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Osteoporosis is a major concern all over the world. With aging, a gradual loss of bone mass results in osteopenia and osteoporosis. Heritable factors account for 60-80% of optimal bone mineralization. Modifiable factors, such as weight-bearing exercise, nutrition, body mass, and hormonal milieu, play an important role in the development of osteopenia and osteoporosis in adulthood. Currently, anti-resorptive agents, including estrogen, bisphosphonates, and selective estrogen receptor modulators (SERMs), are the drugs of choice for osteoporosis. Other treatments include parathyroid hormone (PTH) as well as the nutritional support of calcium and vitamin D. New treatments such as tissue-selective estrogen receptor complexes (TSECs) are currently in use too. This review, which is based on a systematic appraisal of the current literature, provides current molecular and genetic opinions on osteoporosis and its medical treatment. It offers evidence-based information to help researchers and clinicians with osteoporosis assessment. However, many issues regarding osteoporosis and its treatment remain unknown or controversial and warrant future investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.